Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alimu Adilijiang"'
Autor:
Toshiki Fukuoka, Akira Kato, Masaki Hirano, Fumiharu Ohka, Kosuke Aoki, Takayuki Awaya, Alimu Adilijiang, Maeda Sachi, Kuniaki Tanahashi, Junya Yamaguchi, Kazuya Motomura, Hiroyuki Shimizu, Yoshitaka Nagashima, Ryo Ando, Toshihiko Wakabayashi, Dasfne Lee-Liu, Juan Larrain, Yusuke Nishimura, Atsushi Natsume
Publikováno v:
iScience, Vol 24, Iss 2, Pp 102074- (2021)
Summary: The transcriptome analysis of injured Xenopus laevis tadpole and mice suggested that Neurod4L.S., a basic-helix-loop-helix transcription factor, was the most promising transcription factor to exert neuroregeneration after spinal cord injury
Externí odkaz:
https://doaj.org/article/6cd8182708364d5086ad0510d3d4d533
Autor:
Alimu Adilijiang, Masaki Hirano, Yusuke Okuno, Kosuke Aoki, Fumiharu Ohka, Sachi Maeda, Kuniaki Tanahashi, Kazuya Motomura, Hiroyuki Shimizu, Junya Yamaguchi, Toshihiko Wakabayashi, Atsushi Natsume
Publikováno v:
Molecules, Vol 24, Iss 17, p 3046 (2019)
Glioblastoma (GBM), the most common and malignant brain tumor, is classified according to its isocitrate dehydrogenase (IDH) mutation status in the 2016 World Health Organization (WHO) brain tumor classification scheme. The standard treatment for GBM
Externí odkaz:
https://doaj.org/article/7d73ff00955d475896b98f091c533aae
Autor:
Shintaro Yamazaki, Fumiharu Ohka, Yotaro Kitano, Kosuke Aoki, Yutaka Kondo, Takashi Tsujiuchi, Hiroyuki Shimizu, Alimu Adilijiang, Kuniaki Tanahashi, Yukihiro Shiraki, Toshihiko Wakabayashi, Kazuya Motomura, Atsushi Enomoto, Akira Kato, Ryuta Saito, Sachi Maeda, Atsushi Natsume, Masaki Hirano, Ayako Motomura, Keiko Shinjo, Junya Yamaguchi, Yoshiteru Murofushi
Publikováno v:
Neuro Oncol
Background Recent comprehensive studies have revealed several molecular alterations that are frequently found in meningiomas. However, effective treatment reagents targeting specific molecular alterations have not yet been identified because of the l
Autor:
Kazuhiko Mishima, Atsushi Natsume, Yasuo Iwadate, Takanori Onishi, Toshihiko Wakabayashi, Tomokazu Aoki, Kazuhiko Sugiyama, Tamio Ito, Eiichi Ishikawa, Yusuke Okuno, Yoshitaka Narita, Toshihiro Kumabe, Takaaki Beppu, Ryo Nishikawa, Koji Yoshimoto, Masaki Hirano, Kenichiro Asano, Kaoru Kurisu, Kazuya Motomura, Hideo Nakamura, Yoshiki Arakawa, Nobusada Shinoura, Minako Sumi, Kosuke Aoki, Shinya Sato, Fumiyuki Yamasaki, Akio Asai, Tatsuya Abe, Soichiro Shibui, Motoo Nagane, Hiroyuki Kobayashi, Takayuki Matsuo, Akitake Mukasa, Hikaru Sasaki, Yoshihiro Muragaki, Atsuo Yoshino, Akira Matsumura, Fumiharu Ohka, Yoko Nakasu, Sachi Maeda, Mizuhiko Terasaki, Hirofumi Hirano, Alimu Adilijiang, Takamasa Kayama, Naoya Hashimoto, Takashi Maruyama
Publikováno v:
Journal of Neuro-Oncology. 148:17-27
This study aimed to explore the genetic alterations and to identify good responders in the experimental arm in the tumor samples from newly diagnosed glioblastoma (GBM) patients enrolled in JCOG0911; a randomized phase II trial was conducted to compa
Autor:
Kuniaki Tanahashi, Yusuke Nishimura, Alimu Adilijiang, Toshihiko Wakabayashi, Toshiki Fukuoka, Junya Yamaguchi, Juan Larraín, Maeda Sachi, Fumiharu Ohka, Hiroyuki Shimizu, Yoshitaka Nagashima, Dasfne Lee-Liu, Atsushi Natsume, Kazuya Motomura, Takayuki Awaya, Akira Kato, Masaki Hirano, Ryo Ando, Kosuke Aoki
Publikováno v:
iScience
iScience, Vol 24, Iss 2, Pp 102074-(2021)
iScience, Vol 24, Iss 2, Pp 102074-(2021)
Summary The transcriptome analysis of injured Xenopus laevis tadpole and mice suggested that Neurod4L.S., a basic-helix-loop-helix transcription factor, was the most promising transcription factor to exert neuroregeneration after spinal cord injury (
Autor:
Junya Yamaguchi, Kazuya Motomura, Hiroyuki Shimizu, Atsushi Natsume, Kuniaki Tanahashi, Toshihiko Wakabayashi, Masaki Hirano, Yusuke Okuno, Sachi Maeda, Kosuke Aoki, Fumiharu Ohka, Alimu Adilijiang
Publikováno v:
Molecules, Vol 24, Iss 17, p 3046 (2019)
Molecules
Volume 24
Issue 17
Molecules
Volume 24
Issue 17
Glioblastoma (GBM), the most common and malignant brain tumor, is classified according to its isocitrate dehydrogenase (IDH) mutation status in the 2016 World Health Organization (WHO) brain tumor classification scheme. The standard treatment for GBM